Significance Of Evidence For Cell Therapeutics' Pixuvri Is On The Line
Delay in ODAC review - now rescheduled for March 22 - gave Cell Therapeutics time to respond to concerns raised in FDA's briefing material released in February.
Delay in ODAC review - now rescheduled for March 22 - gave Cell Therapeutics time to respond to concerns raised in FDA's briefing material released in February.